Objective
Cognitive impairment is one of the nonmotor symptoms in Parkinson’s disease (PD), and olfactory dysfunction is used as a marker to detect premotor stages of PD. Serum uric acid (sUA) levels have been found to be a risk factor for PD. Our objective in this study was to examine whether sUA levels are associated with cognitive changes and olfactory dysfunction in early de novo PD patients.
Methods
The study participants included 196 de novo PD patients. We assessed cognitive function by the Korean versions of the Mini-Mental State Examination and the Montreal Cognitive Assessment and assessed olfactory function by the Korean version of the Sniffin’ Sticks test.
Results
The mean sUA level was 4.7 mg/dL and was significantly lower in women than in men. Cognitive scores were lower in women, suggesting that sUA levels were related to cognitive function. The olfactory functions were not related to sUA level but were clearly associated with cognitive scores. Olfactory threshold, odor discrimination, and odor identification were all significantly related to cognitive scores.
Conclusion
We conclude that lower sUA levels were associated with cognitive impairment, not olfactory dysfunction, in de novo PD patients. This finding suggests that UA is neuroprotective as an antioxidant in the cognitive function of PD patients.
Citations
Citations to this article as recorded by
Relationships between Serum Lipid, Uric Acid Levels and Mild Cognitive Impairment in Parkinson's Disease and Multiple System Atrophy Xiaoqiao Ren, Pan Wang, Hao Wu, Shuai Liu, Jinhong Zhang, Xiyu Li, Yong Ji, Zhihong Shi Journal of Integrative Neuroscience.2024;[Epub] CrossRef
Serum uric acid and Parkinson's disease: A systematic review and meta‐analysis Mohammad Balabandian, Sarvenaz Salahi, Behnaz Mahmoudvand, Mahla Esmaeilzadeh, Seyedeh Melika Hashemi, Fardin Nabizadeh Neurology and Clinical Neuroscience.2023; 11(6): 299. CrossRef
International consensus statement on allergy and rhinology: Olfaction Zara M. Patel, Eric H. Holbrook, Justin H. Turner, Nithin D. Adappa, Mark W. Albers, Aytug Altundag, Simone Appenzeller, Richard M. Costanzo, Ilona Croy, Greg E. Davis, Puya Dehgani‐Mobaraki, Richard L. Doty, Valerie B. Duffy, Bradley J. Goldstein, David International Forum of Allergy & Rhinology.2022; 12(4): 327. CrossRef
Association of serum uric acid and non-motor symptoms in Parkinson's disease Olanike A. Odeniyi, Oluwadamilola O. Ojo, Ifedayo Adeola Odeniyi, Njideka Ulunma Okubadejo Journal of Clinical Sciences.2022; 19(3): 104. CrossRef
A postmortem study suggests a revision of the dual-hit hypothesis of Parkinson’s disease Per Borghammer, Mie Kristine Just, Jacob Horsager, Casper Skjærbæk, Anna Raunio, Eloise H. Kok, Sara Savola, Shigeo Murayama, Yuko Saito, Liisa Myllykangas, Nathalie Van Den Berge npj Parkinson's Disease.2022;[Epub] CrossRef
What substance P might tell us about the prognosis and mechanism of Parkinson's disease? Paola Tirassa, Tommaso Schirinzi, Marcello Raspa, Massimo Ralli, Antonio Greco, Antonella Polimeni, Roberta Possenti, Nicola Biagio Mercuri, Cinzia Severini Neuroscience & Biobehavioral Reviews.2021; 131: 899. CrossRef
Brain-First versus Gut-First Parkinson’s Disease: A Hypothesis Per Borghammer, Nathalie Van Den Berge, Teus van Laar Journal of Parkinson's Disease.2019; 9(s2): S281. CrossRef